Immunome Stock In The News
| IMNM Stock | USD 11.53 0.38 3.41% |
Our overall analysis of Immunome's news coverage and content from conventional and social sources shows investors' bearish mood towards Immunome. The specific impact of Immunome news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Immunome's overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Immunome headlines in addition to utilizing other, more conventional financial analysis modules. Check out Immunome Backtesting and Immunome Hype Analysis. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.
Immunome |
Immunome Today Top News and Investor Outlook
Immunome Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Immunome and other traded companies coverage with news coverage. We help investors stay connected with Immunome headlines for the 27th of November to make an informed investment decision based on correlating the impacts of news items on Immunome Stock performance. Please note that trading solely based on the Immunome hype is not for everyone as timely availability and quick action are needed to avoid losses.
Immunome stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Immunome earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Immunome that are available to investors today. That information is available publicly through Immunome media outlets and privately through word of mouth or via Immunome internal channels. However, regardless of the origin, that massive amount of Immunome data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Immunome news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Immunome relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Immunome's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Immunome alpha.
Immunome Largest EPS Surprises
Earnings surprises can significantly impact Immunome's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-08-16 | 2021-06-30 | -0.39 | -0.46 | -0.07 | 17 | ||
2024-08-09 | 2024-06-30 | -0.39 | -0.49 | -0.1 | 25 | ||
2021-03-25 | 2020-12-31 | -0.29 | -0.4 | -0.11 | 37 | ||
2022-03-28 | 2021-12-31 | -0.81 | -0.68 | 0.13 | 16 | ||
2021-11-15 | 2021-09-30 | -0.5 | -0.65 | -0.15 | 30 | ||
2023-11-09 | 2023-09-30 | -0.17 | -0.36 | -0.19 | 111 |
Immunome Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Immunome Stock. Current markets are strongly bearish. About 82% of major world exchanges and indexes are down. See today's market update for more information.
25th of November 2024
Insider Buying Robert Lechleider Acquires Shares of Immunome Inc at gurufocus.com
22nd of November 2024
Acquisition by Clay Siegall of 33943 shares of Immunome at 9.7787 subject to Rule 16b-3 at seekingalpha.com
15th of November 2024
Redmile Group, LLC Increases Stake in Amicus Therapeutics Inc at gurufocus.com
13th of November 2024
FMR LLCs Strategic Acquisition of Immunome Inc Shares at gurufocus.com
5th of November 2024
Immunome to Present at Guggenheims Inaugural Healthcare Innovation Conference at businesswire.com
1st of November 2024
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635 at businesswire.com
30th of October 2024
Immunome Acquires Zentalis Pharmaceuticals Licensed Assets IMMUNOME, Inc. made a recent si... at thelincolnianonline.com
8th of October 2024
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635 at businesswire.com
13th of September 2024
Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment ... at businesswire.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Immunome in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Immunome's short interest history, or implied volatility extrapolated from Immunome options trading.
Check out Immunome Backtesting and Immunome Hype Analysis. To learn how to invest in Immunome Stock, please use our How to Invest in Immunome guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunome. If investors know Immunome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunome listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.94) | Revenue Per Share 0.189 | Quarterly Revenue Growth (0.18) | Return On Assets (0.40) | Return On Equity (2.76) |
The market value of Immunome is measured differently than its book value, which is the value of Immunome that is recorded on the company's balance sheet. Investors also form their own opinion of Immunome's value that differs from its market value or its book value, called intrinsic value, which is Immunome's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunome's market value can be influenced by many factors that don't directly affect Immunome's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunome's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunome is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunome's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.